Can AI Outsmart the Trickiest Viruses? Researchers Are Rethinking How Vaccines Are Designed

Instead of forcing vaccines to target viral proteins that constantly shift shape, a new research strategy proposes fighting flexibility with flexibility—using generative AI, humanized immune models and unusually adaptable antibodies to design vaccines against some of medicine’s hardest targets.

Viruses have a frustrating habit of refusing to sit still.

Some of the most difficult viral targets aren't simply changing through mutation. The proteins sitting on their surfaces can physically move, bend and shift between different conformations, making them extraordinarily difficult for antibodies to recognize consistently. A vaccine may train the immune system to recognize one version of an antigen, only for that target to present itself differently when the antibody encounters it again.

A research proposal titled “Fighting Fire with a Fire: Rational Vaccine Design to Target Conformationally Dynamic Viral Antigens with Intrinsically Flexible Antibodies” is taking that problem and turning it into the basis of an entirely different vaccine strategy.

Instead of trying to make the immune system recognize a moving target with a rigid response, the researchers want to deliberately stimulate antibody lineages capable of being flexible themselves.

And they plan to use generative artificial intelligence to help find the vaccine designs most likely to make that happen.

The Problem Isn't Always Mutation. Sometimes It's Movement.

Traditional vaccine design generally depends on presenting the immune system with an antigen that teaches B cells to produce useful antibodies. But conformationally dynamic viral proteins complicate that process because the three-dimensional structure of the target isn't necessarily fixed.

Think of trying to create a key for a lock that keeps subtly changing shape.

The proposed research focuses on directing the immune system toward protective B-cell lineages that may be unusually well suited to recognizing these flexible epitopes. One of particular interest is VH1-69, an antibody gene segment associated with recognition of flexible viral epitopes and viral clearance.

Rather than hoping vaccination happens to generate the desired antibody response, the researchers want to engineer immunogens specifically designed to steer B cells toward those protective lineages.

That's where AI enters the picture.

Generative AI Could Search Trillions of Possible Vaccines

The first part of the strategy uses generative AI-based protein design tools to create self-assembling, stabilized immunogens engineered to stimulate the types of B cells researchers want.

Protein design creates an almost unimaginably large search space. There are far too many potential structures and combinations for researchers to experimentally build and test one at a time.

AI changes the scale of that search.

According to the proposal, computational tools could screen trillions of potential designs, rapidly narrowing the field to candidates predicted to have the characteristics most likely to generate broadly neutralizing antibodies.

The goal isn't simply to use AI because it is faster. It's to make vaccine design more intentional.

Instead of starting with a viral antigen and asking, “What immune response does this produce?” researchers are moving toward a different question: “What immune response do we want, and what antigen should we build to produce it?”

That's a significant conceptual shift.

Then Comes a Problem Vaccine Researchers Know Well: Mice Aren't Humans

Designing an impressive immunogen on a computer is only the beginning. Researchers still need to determine what an actual immune system does with it.

Traditional mouse models are enormously valuable in biomedical research, but mouse antibodies aren't human antibodies. Differences in immunoglobulin genes mean a vaccine capable of producing a promising antibody response in conventional mice may not necessarily generate the same response in people.

The proposed work attempts to close that gap by using humanized mice expressing human immunoglobulin genes.

These animals would provide researchers with a preclinical model that more closely reflects the antibody repertoire available to a human immune system. That becomes especially important when the entire vaccine strategy depends on deliberately activating particular human antibody lineages.

If the researchers want a vaccine to stimulate something like VH1-69, they need a model capable of producing the relevant human antibody response in the first place.

A High Antibody Titer Doesn't Tell the Whole Story

The project also challenges another familiar way of evaluating vaccines.

Researchers traditionally look at measurements such as antibody levels and neutralizing titers to determine whether a vaccine is producing a useful immune response. Those measurements are important, but they don't necessarily explain exactly which parts of a virus the antibodies recognize.

This team wants a much higher-resolution picture.

The researchers have developed what they call epitope knockout probes, tools designed to determine the specific viral epitopes recognized by vaccine-induced B cells and antibodies.

Rather than simply concluding that a vaccine generated antibodies, researchers could begin determining which B cells responded, which epitopes those cells recognize, what B-cell receptor sequences they carry and what the resulting antibodies actually look like structurally.

That information could reveal why one vaccine candidate produces broadly protective antibodies while another generates a large but less useful immune response.

The Vaccine Could Essentially Teach Researchers How to Build Its Replacement

Perhaps the most interesting part of the proposal is the feedback loop researchers hope to create.

After vaccination, scientists would map the epitopes recognized by responding B cells. They would connect those responses to individual B-cell receptor sequences and determine the structures of the resulting antibodies.

That information could then be fed back into the design process.

If an immunogen successfully directs the immune system toward a desirable antibody lineage, researchers can study exactly how it accomplished that. If it stimulates the wrong response, they can identify what happened and redesign the immunogen accordingly.

The next generation of computationally designed candidates could therefore be informed by the immune responses generated by the previous generation.

Design. Vaccinate. Map the response. Study the antibodies. Redesign.

Rather than vaccine development being a largely linear process, it becomes iterative.

This Could Matter Far Beyond One Virus

The researchers ultimately aren't proposing a strategy for only a single vaccine. They hope to develop a broader roadmap for attacking biological targets that have historically been difficult precisely because they are structurally flexible.

If scientists can learn how to deliberately generate antibodies capable of recognizing conformationally dynamic targets, the implications could extend beyond infectious disease.

The proposal suggests that similar principles could eventually inform therapeutic strategies involving autoimmune disease and cancer, where recognizing difficult or changing biological targets can also be critical.

There is still an enormous distance between a compelling research strategy and a vaccine that protects people in the real world. Computational predictions need experimental validation. Immune responses in humanized mice still aren't the same thing as responses in human patients. Safety, durability, breadth of protection and clinical effectiveness would all ultimately have to be established.

But the project illustrates where vaccine science is heading.

Artificial intelligence isn't simply being asked to analyze experimental results after scientists have designed a vaccine. It is increasingly being brought into the earliest stages of biological design, helping researchers decide what molecules should exist in the first place.

At the same time, increasingly sophisticated immunology is allowing researchers to examine vaccine responses at the level of individual B-cell lineages, epitopes, receptor sequences and antibody structures.

Put those technologies together and vaccine development starts looking very different.

For viruses that have spent millions of years becoming exceptionally good at escaping the immune system, researchers may finally be able to respond with some sophisticated tricks of their own.

If the viral target refuses to hold still, perhaps the answer isn't forcing it to.

Maybe the answer is designing an antibody that knows how to move with it.

Source: “Fighting Fire with a Fire: Rational Vaccine Design to Target Conformationally Dynamic Viral Antigens with Intrinsically Flexible Antibodies.” This article is based on the research strategy described in the provided project summary; the proposed approaches and potential applications should not be interpreted as established clinical efficacy.